All News

Infectious disease expert Amesh Adalja, MD, discusses new vaccine policies, misinformation, and how PCPs can build confidence during National Immunization Awareness Month.

"The foundation of science in the new iteration of the ACIP is uncertain at best," William Schaffner, MD, observed. He is concerned about where that might lead.

Family physician Sarah Sams, MD, shares practical strategies on vaccine updates, coadministration, and addressing hesitancy this respiratory season.

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.

Your daily dose of the clinical news you may have missed.

The accelerated approval for semaglutide 2.4 mg for the treatment of noncirrhotic MASH was based on part 1 of the phase 3 ESSENCE trial, which met its primary endpoints.

The US FDA approved Tonmya, a groundbreaking treatment for fibromyalgia, offering hope to millions experiencing chronic pain and sleep issues.

Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.